Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比(1)
摘 要：目的 比較辅助化疗XELOX方案、FOLFOX方案对Ⅱ、Ⅲ期结肠癌患者的临床疗效、不良反应及生活质量的差异。方法 收集2009年1月～2012年1月解放军第二五四医院普通外科收治的行根治性手术切除的171例结肠癌患者的临床资料，按数字随机分为两组，90例患者术后接受XELOX化疗方案，81例接受FOLFOX化疗方案。比较两组患者的无病生存期、5年生存率、不良反应发生及生存质量的差异。结果 XELOX组34例(37.78%)出现病情进展，FOLFOX组28例(34.57%)出现病情进展。XELOX组、FOLFOX组的3年无病生存率对比，差异无统计学意义(P>0.05)。XELOX组死亡21例(23.33%)。FOLFOX组死亡19例(23.46%)。Log-rank检验结果显示，两组患者5年生存率对比，差异无统计学意义(P>0.05)。两组患者恶性呕吐、高胆红血症的不良反应发生率，差异无统计学意义(P>0.05)。神经毒性、腹泻、白细胞减少、粒细胞减少、血小板减少、口腔黏膜炎的发生率，FOLFOX组高于XELOX组，差异有统计学意义(P<0.05)。XELOX组手足综合征的发生率高于XELOX组，差异有统计学意义(P<0.05)。两组患者在化疗的不同阶段，情绪状况、功能状况、身体状况、社会/家庭状况、总体生存质量等5个纬度，差异均无统计学意义(P>0.05)。 结论 对Ⅱ、Ⅲ期结肠癌患者而言，XELOX方案与FOLFOX方案在提高术后无病生存期、5年生存率及生活质量方面无明显差异。但XELOX方案不良反应更少，患者的依从性与耐受性更好。
, 百拇医药
关键词：结肠癌；卡培他滨；奥沙利铂；氟尿嘧啶
中图分类号：R735.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.020
文章编号：1006-1959(2018)13-0068-05
Abstract：Objective To compare the clinical efficacy， adverse reactions and quality of life of patients with stage II and III colon cancer by XELOX and FOLFOX.Methods The clinical data of 171 patients with colon cancer who underwent radical surgery for general surgery in the 254th Hospital of Chinese People's Liberation Army from January 2009 to January 2012 were collected.They were randomly divided into two groups according to the number.90 patients received XELOX chemotherapy after operation and 81 patients received FOLFOX chemotherapy.The disease-free survival，5-year survival rate，adverse reaction occurrence and quality of life were compared between the two groups.Results In the XELOX group，34 patients(37.78%)developed disease progression，and 28 patients(34.57%)in the FOLFOX group developed disease progression.There was no significant difference in the 3-year disease-free survival rate between the XELOX group and the FOLFOX group(P>0.05).21 patients(23.33%)died in the XELOX group.19 patients (23.46%)died in the FOLFOX group.Log-rank test results showed that there was no significant difference in the 5-year survival rate between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between malignant vomiting and hyperbilirubinemia between the two groups(P>0.05).The incidence of neurotoxicity，diarrhea，leukopenia，neutropenia， thrombocytopenia，and oral mucositis was higher in the FOLFOX group than in the XELOX group，the difference was statistically significant(P<0.05).The incidence of hand-foot syndrome in the XELOX group was higher than that in the XELOX group，and the difference was statistically significant(P<0.05).There were no significant differences in the five latitudes between the two groups at different stages of chemotherapy，such as emotional status，functional status，physical condition，social/family status，and overall quality of life(P>0.05).Conclusion For patients with stage II and III colon cancer，there is no significant difference between the XELOX regimen and the FOLFOX regimen in improving postoperative disease-free survival，5-year survival，and quality of life.However，the XELOX regimen has fewer side effects and better patient compliance and tolerance., 百拇医药(石磊 孙新增 李宝山 白建平)
, 百拇医药
关键词：结肠癌；卡培他滨；奥沙利铂；氟尿嘧啶
中图分类号：R735.3 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.020
文章编号：1006-1959(2018)13-0068-05
Abstract：Objective To compare the clinical efficacy， adverse reactions and quality of life of patients with stage II and III colon cancer by XELOX and FOLFOX.Methods The clinical data of 171 patients with colon cancer who underwent radical surgery for general surgery in the 254th Hospital of Chinese People's Liberation Army from January 2009 to January 2012 were collected.They were randomly divided into two groups according to the number.90 patients received XELOX chemotherapy after operation and 81 patients received FOLFOX chemotherapy.The disease-free survival，5-year survival rate，adverse reaction occurrence and quality of life were compared between the two groups.Results In the XELOX group，34 patients(37.78%)developed disease progression，and 28 patients(34.57%)in the FOLFOX group developed disease progression.There was no significant difference in the 3-year disease-free survival rate between the XELOX group and the FOLFOX group(P>0.05).21 patients(23.33%)died in the XELOX group.19 patients (23.46%)died in the FOLFOX group.Log-rank test results showed that there was no significant difference in the 5-year survival rate between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between malignant vomiting and hyperbilirubinemia between the two groups(P>0.05).The incidence of neurotoxicity，diarrhea，leukopenia，neutropenia， thrombocytopenia，and oral mucositis was higher in the FOLFOX group than in the XELOX group，the difference was statistically significant(P<0.05).The incidence of hand-foot syndrome in the XELOX group was higher than that in the XELOX group，and the difference was statistically significant(P<0.05).There were no significant differences in the five latitudes between the two groups at different stages of chemotherapy，such as emotional status，functional status，physical condition，social/family status，and overall quality of life(P>0.05).Conclusion For patients with stage II and III colon cancer，there is no significant difference between the XELOX regimen and the FOLFOX regimen in improving postoperative disease-free survival，5-year survival，and quality of life.However，the XELOX regimen has fewer side effects and better patient compliance and tolerance., 百拇医药(石磊 孙新增 李宝山 白建平)